Trigeminal autonomic cephalgia

electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting

Retrieved on: 
Tuesday, June 13, 2023
SUNA, ECOR, Poster, Headache, NVN, Jesse Russell, Patient, Trigeminal autonomic cephalgia, ElectroCore, Rare-earth element, Pharmaceutical industry

ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.

Key Points: 
  • ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.
  • The abstract and poster highlight the observed efficacy of nVNS in three patients with rare headache diseases, SUNCT/SUNA, in the class of headache disorders known as Trigeminal Autonomic Cephalalgia’s (“TACs”).
  • The retrospective study suggests that nVNS, as a treatment for TACs in general, and specifically for refractory SUNCT/ SUNA, should be considered before microvascular neurosurgery, particularly given the well-recognized risks and costs of such surgical procedures.

electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance

Retrieved on: 
Wednesday, August 4, 2021
Headaches, Symptoms and signs, Branches of biology, Medicine, Trigeminal autonomic cephalgia, Migraine, Cluster headache, Hemicrania continua, Headache, Medication overuse headache, International Classification of Headache Disorders

The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.

Key Points: 
  • The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.
  • The aim of the guidance is to support the adoption of clinically effective and cost-saving technologies in the UK National Health Service.
  • PharmacoEconomics reiterating the evidence supporting gammaCores effectiveness and economic benefit provides further support that gammaCore can play an important role in providing value-based therapy commented Iain Strickland, VP Global Sales and Strategy of electroCore.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

Migraine and Headache Awareness Month: gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Treats & Prevents Migraine and Cluster Headaches

Retrieved on: 
Tuesday, June 8, 2021
General Health, Health, Other Health, Medical devices, Headaches, Symptoms and signs, Medicine, Clinical medicine, Trigeminal autonomic cephalgia, Migraine, Medication overuse headache, Hemicrania continua, Cluster headache, Headache, International Classification of Headache Disorders, NIH classification of headaches, electroCore, Inc, gammaCore, ELECTROCORE, INC, GAMMACORE

Successful treatment with gammaCore may generate savings for patients and provide overall benefit by preventing attacks, reducing pain intensity and frequency.

Key Points: 
  • Successful treatment with gammaCore may generate savings for patients and provide overall benefit by preventing attacks, reducing pain intensity and frequency.
  • gammaCore may also help reduce medical costs for migraine including frequent doctors visits and pharmaceuticals or other treatments.
  • The companys current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

electroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23

Retrieved on: 
Thursday, March 19, 2020
Headaches, Medicine, Clinical medicine, Organ systems, Trigeminal autonomic cephalgia, Cluster headache, Hemicrania continua, Migraine, Medication overuse headache, Headache, International Classification of Headache Disorders, Vagus nerve stimulation

electroCore is a commercial stage bioelectronic medicine company with a proprietary non-invasive vagus nerve stimulation, or nVNS, therapy.

Key Points: 
  • electroCore is a commercial stage bioelectronic medicine company with a proprietary non-invasive vagus nerve stimulation, or nVNS, therapy.
  • nVNS is a platform therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
  • gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute treatment of pain associated with migraine headache in adult patients.

NICE Recommends the Use of gammaCore for the Treatment of Cluster Headache in the NHS

Retrieved on: 
Tuesday, December 3, 2019
Headaches, Medicine, Clinical medicine, Pain, Trigeminal autonomic cephalgia, Cluster headache, Medication overuse headache, Migraine, International Classification of Headache Disorders, Hemicrania continua, Headache

I would like to thank all of the headache specialists, patients affected by cluster headache, and the Organisation for the Understanding of Cluster Headache (OUCH), who, amongst many others, shared their experiences of both cluster headache and gammaCore, as part of the NICE consultation process.

Key Points: 
  • I would like to thank all of the headache specialists, patients affected by cluster headache, and the Organisation for the Understanding of Cluster Headache (OUCH), who, amongst many others, shared their experiences of both cluster headache and gammaCore, as part of the NICE consultation process.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
  • gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute treatment of pain associated with migraine headache in adult patients.
  • The companys primary focus in the UK is the use of gammaCore for the treatment of cluster headache and migraine.